LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.
—
Filed today
—
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there — you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings —
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
The company's board reviewed and approved its latest financial update for the second quarter and first half of the fiscal year.
🤖 AI Summary
Board of Directors approved Q2 and H1 FY27 unaudited standalone financial results.
Results are for the period ended September 30, 2026.
Limited review report from Statutory Auditor was also considered.
Board meeting held on October 30, 2026, at the company's corporate office.
🏢 How This Affects the Company
💰
Financial Impact
The approval of the un-audited financial results provides an update on the company's financial performance for the specified periods.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this board meeting outcome.
👤
Who Is Affected
All shareholders are affected by the disclosure of the company's financial performance.
🔍
Management Signal
The board is adhering to its quarterly reporting schedule and regulatory obligations.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarter's financial results disclosure
Any updates on strategic business developments
Annual General Meeting announcements
LOW RISKThis is a standard financial results disclosure meeting outcome.
💡 Investor Takeaway
Genomic Valley Biotech's Board of Directors has officially approved the un-audited financial results for the quarter and half-year ended September 30, 2026, along with the auditor's limited review report.
❓ Frequently Asked Questions
What did the Genomic Valley Biotech board approve on October 30, 2026?
The board approved the un-audited financial results for the quarter and half-year ended September 30, 2026.
When was the Genomic Valley Biotech board meeting held?
The board meeting was held on Wednesday, October 30, 2026.
What other report was considered alongside the financial results?
A limited review report from the Statutory Auditor was also considered by the board.
Questions based on this BSE filing only. For information purposes.
All BSE filings we have analysed for Genomic Valley Biotech Ltd.
You've read one filing
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again — explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.